研究显示 GLP-1 受体激动剂与精神分裂症合并 2 型糖尿病患者的精神科住院及急诊风险降低相关
Schizophrenia and type 2 diabetes are linked, but GLP-1s could help manage the risks
一项发表于 The Lancet Psychiatry 的观察性队列研究分析美国 7 万余名精神分裂症合并 2 型糖尿病患者的电子健康记录,发现使用 GLP-1 受体激动剂(semaglutide、liraglutide、tirzepatide、dulaglutide)者,其精神科住院风险较未使用新型降糖药者低 24%,急诊就诊风险低 29%。
Treatment with glucagon-like peptide-1 receptor agonists (GLP-1s) was associated with lower risks of psychiatric hospitalization and psychiatric emergency department visits in people with both schizophrenia and type 2 diabetes (T2D), compared with no GLP-1 treatment or treatment with newer diabetes medications, according to new research published in The Lancet Psychiatry.
Schizophrenia is associated with an increased risk of T2D, and antipsychotic medications prescribed for schizophrenia also increase the risk of T2D. GLP-1s are an established class of diabetes medication used to treat people with T2D; however, whether GLP-1s affect the mental health of people with schizophrenia remains uncertain.
Researchers analyzed U.S. health records for more than 70,000 adults with both schizophrenia and type 2 diabetes, treated between January 2018 and October 2026. Some had been prescribed a GLP-1 (either semaglutide, liraglutide, tirzepatide or dulaglutide); others had been prescribed a newer type of diabetes medication (a DPP-4 inhibitor or an SGLT2 inhibitor); and some had not been prescribed any of these treatments.
People taking GLP-1s were 24% less likely to need psychiatric hospital admission than those not taking any of these diabetes medications, 18% less likely than those taking DPP-4 inhibitors and 17% less likely than those taking SGLT2 inhibitors. They were also less likely to need emergency department care for a mental health crisis: 29% less likely than those not on any of these diabetes medications, 13% less likely than those on DPP-4 inhibitors and 20% less likely than those on SGLT2 inhibitors.
The association between treatment with GLP-1s and lower risk of psychiatric acute care was strongest in people who lost weight, but was also seen, to a lesser extent, in those whose weight stayed stable and those who gained weight, suggesting the effect may not be driven by weight loss alone. When each specific GLP-1 treatment was analyzed separately, the association was seen with semaglutide, liraglutide and tirzepatide, but not dulaglutide.
The authors note that these observational data cannot show that GLP-1s directly cause the reduced risk of needing acute psychiatric care, and say GLP-1s should not be considered a primary psychiatric treatment or prescribed solely to reduce psychiatric acute-care use. However, the authors say their findings support a potential role for GLP-1s within integrated cardiometabolic and mental health care. Future clinical trials are needed to confirm these findings, including in people with schizophrenia but without T2D.
Publication details
Najmeh Davoodian et al., GLP-1 receptor agonist initiation and risk of psychiatric hospitalisation and emergency department presentation in adults with schizophrenia and type 2 diabetes in the USA: an observational cohort study using electronic health records data, The Lancet Psychiatry (2026). DOI: 10.1016/s2215-0366(26)00276-2
Journal information: The Lancet Psychiatry
Who's behind this story?
Lisa Lock
BA art history, MA material culture. Former museum editor, paramedic, and transplant coordinator. Editing for Science X since 2021. Full profile →
Alexander Pol
PhD nano-engineering from Delft University. Published researcher and journal reviewer. Brings scientific insight to content standards. Full profile →
Citation: Schizophrenia and type 2 diabetes are linked, but GLP-1s could help manage the risks (2026, October 15) retrieved 15 October 2026 from https://medicalxpress.com/news/2026-10-schizophrenia-diabetes-linked-glp-1s.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
来源:Medical Xpress · medicalxpress.com